MEA Schizoaffective Disorders Treatment Market

MEA Schizoaffective Disorders Treatment Market Size (2022 to 2027):

As per the research report, the size of the Middle East and Africa Schizoaffective Disorders Treatment Market is valued at USD xx billion in 2022 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2027, during the forecast period 2022 to 2027.

Schizoaffective Disorder is a mental disorder which is characterized by deregulated emotions and thought processes and. The diagnosis is made when the person has features of both a mood disorder—either bipolar disorder or depression, and schizophrenia but does not meet the diagnostic criteria for either alone strictly. The bipolar type is distinguished by symptoms of hypomania, mania, or mixed episode; the depressive type only by symptoms of depression. Common symptoms of the disorder include paranoid delusions, hallucinations, and disorganized thinking and speech. The onset of symptoms usually begins in young times of adulthood, presently with an uncertain lifetime prevalence since the disorder was redefined in DSM-IV.  Diagnosis is based on the person's reported experiences observed behaviour.

Neurobiology, genetics, early and current environment, social, behavioural, and experiential components appear to be important contributory factors; some prescription and recreational drugs may worsen or cause symptoms. People with schizoaffective disorder are likely to have co-occurring conditions, including substance use disorder and anxiety disorders. Social problems such as long-term unemployment, homelessness and poverty are common. The average life expectancy of people with the disorder is less than those without it, due to rise of problems related to physical health from an absence of health promoting behaviours including a higher suicide rate and a sedentary lifestyle.

The driving factors of Middle East and Africa Schizoaffective Disorders Treatment market are rapidly rising sedentary life style, increasing healthcare spending, growing prevalence of chronic diseases, availability of advanced healthcare treatments and increasing awareness about schizoaffective disorders. While on the other hand, stringent regulatory approval procedures, social stigma associated with schizoaffective disorders, and lack of diagnosis at right time are some of the factors that are constraining the growth of the Middle East and Africa schizoaffective disorders treatment market.

This research report on the MEA Schizoaffective Disorders Treatment Market has been segmented and sub-segmented into the following categories.

By Treatment:

• Antipsychotics
• Mood Stabilisers
• Antidepressants
• Anticonvulsants
• Psychotherapy

By Cause of Disorder:

• Genetic Factors
• Chemical Factors
• Environmental Factors                      

By Type:

• Manic Type
• Depressive Type
• Mixed Type
• Schizoaffective Disorders                             

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA Schizoaffective disorders treatment market is anticipated to reach at decent CAGR due to improving healthcare facilities, large patient base and growing awareness about mental health disorders among the population during the forecast period.

The South Africa Schizoaffective disorders treatment market is expected to grow due to the high prevalence of schizoaffective disorders amongst the people especially in teenagers and middle ages people will propel the market positively.

The UAE schizoaffective disorders treatment market is expected to grow at significant CAGR owing to the high incidence of schizoaffective disorders, developing economies with high purchasing power, improving healthcare infrastructure during the forecast period.

The Saudi Arabia schizoaffective disorders treatment market is estimated to reach at decent heights due to the increased number of taxpayers, early adoption of diagnostics tests in private medical sector and public awareness are anticipated to grow during the forecast period.

KEY MARKET PLAYERS

The leading companies leading in the MEA Schizoaffective Disorders Treatment Market profiled in the report are Merz Pharma GmbH & Co. KGaA., Eli Lilliy and Company, Elan Pharmaceuticals, Ciba Pharmaceuticals, Abbott Pharmaceuticals, AstraZeneca plc, and Janssen-Cilag Pty Limited.,